Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

End of LifeLife & the Law

Assisted Suicide at the Polls: Risks & Rewards Associated with Voting to Legalize Assisted Suicide vs. Maintaining the Status Quo

By Jacqueline H. Abernathy, Ph.D.

 

This academic paper analyzes the significance of a legislator’s position in favor of assisted suicide.  In particular, the paper looks at the risk associated with support for legalization of assisted suicide on subsequent re-election.  This original work comes from the Department of Social Sciences at Tarleton State University, written by Dr. Jacqueline C. Harvey, a political science faculty member. This version of the paper is a conference abstract that was presented at the 2016 Southern Political Science Association Conference.  The full version of the paper will be published in an appropriate academic journal at a later date.

 

To view as PDF, please see: Assisted Suicide at the Polls: Risks & Rewards Associated with Voting to Legalize Assisted Suicide vs. Maintaining the Status Quo

 

 

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

Map: Assisted Suicide in the States

charlotte-lozier-institute Charlotte Lozier Institute
March 3, 2025

Washington State: Expanding Death Without Dignity

Lethal Non-Compliance with Washington’s “Death with Dignity Act”

Lethal Non-Compliance with Washington’s “Death with Dignity Act”

December 20, 2022

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image